HARP Live signals | Maximize Profits with Getagraph.com

BUY 94641 min ago

@ $22.46

Issued: 14 Feb 2024 @ 12:29

Return: 2.45%

Previous signal: Feb 14 - 09:30

Previous signal: Sell

Return: -0.29 %

Live Chart Being Loaded With Signals

Commentary (8 Mar 2024 @ 16:00):

Stats
Today's Volume	6.40M
Average Volume	1.13M
Market Cap	865.08M
EPS	$0 ( 2024-03-25 )
Next earnings date	( $0 ) 2024-05-09
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-15.04
ATR14	$0.377 (1.64%)

Insider Trading

Date	Person	Action	Amount	type
2024-03-11	New Leaf Biopharma Opportunities Ii, L.p.	Sell	395 783	Common Stock
2024-03-11	New Leaf Biopharma Opportunities Ii, L.p.	Sell	10 000	8.000% Series A Redeemable Preferred Stock
2024-03-11	New Leaf Biopharma Opportunities Ii, L.p.	Sell	299 430	Common Stock Warrant (Right to Buy)
2024-03-11	New Leaf Biopharma Opportunities Ii, L.p.	Sell	85 750	Common Stock Warrant (Right to Buy)
2024-03-11	Silvernail Lauren P	Sell	5 000	Common Stock

INSIDER POWER
75.58
Last 96 transactions
Buy: 30 137 007 \| Sell: 5 308 481

Volume Correlation

Long: 0.48 (neutral)

Short: 0.40 (neutral)

Signal:(82.718) Neutral

Harpoon Therapeutics Inc Correlation

10 Most Positive Correlations
APOP	0.898
RMRM	0.892
PAIC	0.857
TDAC	0.851
GAINL	0.843
TLGT	0.841
ISNS	0.821
SVAC	0.813
SPRT	0.808

10 Most Negative Correlations
MMAC	-0.899
BOCH	-0.892
NETE	-0.858
AMRB	-0.844
SHSP	-0.811
DSPG	-0.808

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

Harpoon Therapeutics Inc Correlation - Currency/Commodity

0.60
( weak )

0.63
( weak )

0.85
( strong )

-0.69
( moderate negative )

0.28
( neutral )

-0.39
( neutral )

Harpoon Therapeutics Inc Financials

Annual	2022
Revenue:	$31.92M
Gross Profit:	$28.82M (90.30 %)
EPS:	$-20.24

Q3	2023
Revenue:	$4.45M
Gross Profit:	$4.21M (94.69 %)
EPS:	$-0.460

Q2	2023
Revenue:	$20.22M
Gross Profit:	$19.65M (97.19 %)
EPS:	$0.300

Q1	2023
Revenue:	$8.58M
Gross Profit:	$7.48M (87.13 %)
EPS:	$-3.26

Financial Reports:

No articles found.

Harpoon Therapeutics Inc

Harpoon Therapeutics, Inc., a clinical-stage immunotherapy company, engages in the development of a novel class of T cell engagers that harness the power of the body's immune system to treat patients suffering from cancer and other diseases in the United States. The company develops tri-specific T cell activating construct (TriTAC) product candidate, including HPN328, which is in Phase I/II clinical trials for the treatment of small cell lung cancer and other Delta-like canonical Notch ligand 3-expressing tumors; HPN217 that is in Phase I/II clinical trials for the treatment of multiple myeloma; and HPN536, which is in Phase I/IIa clinical trials for the treatment of ovarian and pancreatic cancer, and other mesothelin-expressing tumors. Its preclinical stage product is HPN601 for the treatment of multiple solid tumor indications. The company has a discovery collaboration and license agreement with AbbVie Biotechnology Ltd. to develop and commercialize products that incorporate its proprietary TriTAC platform technology together with soluble T cell receptors. Harpoon Therapeutics, Inc. was incorporated in 2015 and is headquartered in South San Francisco, California.